Palmitoylethanolamide (PEA) is an endogenous fatty acid amide made inside the body when necessary. Since its discovery in 1954 there have been more than five hundred studies aimed at presenting the benefits and safety of palmitoylethanolamide.
Palmitoylethanolamide (PEA) products
However, this does not mean we thought our work was over. Palmitoylethanolamide has one issue that hampers its innate efficacy. Its half-life is very short as it is quickly degraded by two very efficient enzymes in the body – fatty acid amide hydrolase (FAAH) and N-acylethanolamine acid amide hydrolase (NAAA). This means that the positive effects of palmitoylethanolamide are limited by the efficacy of these enzymes.
We set out to provide the market with a product that is more bioavailable and thus more efficient. After a year of research that tested numerous kinds of improvements of bioavailability without jeopardizing safety and efficacy, we came up with liposomal palmitoylethanolamide which greatly improves bioavailability and absorption. This is so because liposome membranes and cell membranes are biocompatible, so encapsulating palmitoylethanolamide inside a liposome means that PEA is protected from the enzymes and stomach acids and that it is delivered straight to the cells, as well as fully absorbed, since phospholipids of the cell membrane readily accept phospholipids of the liposome membrane.
You can read about our products and PEA in general below